Orally active, ATP-competitive inhibitor of p38α MAPK; also inhibits p38β (KD
values are 3.7 and 17 nM respectively).
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome.
Selective p38α inhibitors clinically evaluated for the treatment of chronic inflammatory disorders.
Goldstein et al.
Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis.
Damjanov et al.
The citations listed below are publications that use Tocris products. Selected citations for VX 702 include:
Showing Results 1 - 1 of 1